Core Viewpoint - Jiangsu Wuzhong (*ST Suwu*) is facing imminent delisting risks due to significant financial losses, operational stagnation, and regulatory violations, with a net profit loss of 87.468 million yuan and a nearly 40% year-on-year revenue decline in the third quarter [3][4]. Group 1: Delisting Risks - The primary risk for Jiangsu Wuzhong is the potential for mandatory delisting due to major violations, as identified by the China Securities Regulatory Commission (CSRC) [5]. - The company has been found guilty of three major violations, including failing to disclose the actual controller, inflating revenue and profits, and not reporting non-operational fund usage by related parties [5][6]. - The stock price has plummeted 88% since the CSRC investigation began, with the latest closing price at 0.99 yuan, hovering near the delisting threshold of 1 yuan [7]. Group 2: Financial Performance - Jiangsu Wuzhong reported a 38.85% decrease in revenue for the first three quarters, totaling 784 million yuan, with a net profit loss of 87.468 million yuan [9]. - The third quarter alone saw a staggering 63.93% year-on-year revenue drop, with a net profit loss of 43.0502 million yuan, marking a significant operational decline [9][10]. - The company's cumulative undistributed losses reached 505 million yuan by the end of the third quarter, the highest since its listing [9]. Group 3: Business Operations - The core pharmaceutical business has seen a 55.79% decline in revenue, while the medical beauty segment, previously seen as a growth driver, is now at risk due to the termination of exclusive distribution rights for a key product [10][11]. - The medical beauty segment's revenue was 303 million yuan, a 52.78% increase, but the loss of exclusive rights for the AestheFill product could severely impact future earnings [10][11]. - The company is facing severe cash flow issues, with operational funds critically low due to significant related party fund usage, which increased from 127 million yuan in 2020 to 1.693 billion yuan in 2023, consuming nearly all net assets [6][9].

Core Viewpoint - Jiangsu Wuzhong (600200.SH) is facing imminent delisting risks due to multiple violations, including significant financial losses and operational stagnation, as highlighted in recent announcements and financial reports [1][2][4]. Group 1: Delisting Risks - Jiangsu Wuzhong has issued a risk warning regarding potential delisting due to a face value breach, with a stock price currently at 0.99 yuan, down 89% year-to-date [1][2]. - The company is under investigation by the China Securities Regulatory Commission (CSRC) for major violations, including failure to disclose the actual controller and inflating financial figures from 2018 to 2023 [2][3]. - The company has been identified as having significant non-operational fund occupation by related parties, with amounts soaring from 127 million yuan in 2020 to 1.693 billion yuan in 2023, representing 96.09% of net assets [3]. Group 2: Financial Performance - Jiangsu Wuzhong reported a net loss of 87.468 million yuan for the first three quarters, with revenue dropping by 38.85% to 784 million yuan [1][4]. - The company's pharmaceutical business saw a 55.79% decline in revenue, while the medical beauty segment, previously seen as a growth area, is now under threat due to the termination of exclusive distribution rights for a key product [5][6]. - The third quarter alone showed a staggering revenue drop of 63.93% compared to the previous quarter, with a net loss of 43.0502 million yuan, marking a significant operational downturn [5][6].

Group 1 - The average stock price of A-shares is 13.84 yuan, with 26 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.38 yuan [1] - Among the low-priced stocks, 9 are ST stocks, accounting for 34.62% of the total [1] - The Shanghai Composite Index closed at 3954.79 points as of October 31 [1] Group 2 - Among the low-priced stocks, 11 increased in price today, with Jin Zheng Da, Rong Sheng Development, and Ya Bo Shares leading with increases of 2.79%, 2.55%, and 2.31% respectively [1] - Conversely, 9 stocks decreased, with *ST Yuan Cheng, Liao Gang Shares, and Shan Ying International showing declines of 4.88%, 4.47%, and 2.21% respectively [1] - The table lists various low-priced stocks along with their latest closing prices, daily price changes, turnover rates, and industry classifications [1][2]

Core Viewpoint - The company *ST Suwu is facing significant risks of forced delisting due to major violations, including financial fraud and multiple delisting indicators, as the transition period for new delisting regulations ends on January 1, 2025 [2][3][4]. Summary by Relevant Sections Major Delisting Risks - *ST Suwu has issued its 16th risk warning regarding potential forced delisting due to major violations [3][6]. - The China Securities Regulatory Commission (CSRC) has identified that *ST Suwu inflated its operating income, costs, and profits in its annual reports from 2020 to 2023, which constitutes a major violation [4][5]. - The company is currently awaiting a formal penalty decision from the CSRC, which could lead to the termination of its stock listing [3][4]. Financial Irregularities - From 2020 to 2023, *ST Suwu inflated its operating income by 495 million, 469 million, 431 million, and 377 million yuan, representing 26.46%, 26.39%, 21.26%, and 16.82% of the reported income for those years, respectively [5]. - The inflated total profits for the same years were 14.58 million, 20.27 million, 19.92 million, and 21.22 million yuan, accounting for 2.89%, 51.65%, 26.42%, and 29.81% of the reported profits [5]. Additional Delisting Pressures - The company is also under pressure for a 1 yuan face value delisting, having entered the observation period for this risk due to its stock price falling below 1 yuan for consecutive trading days [7][8]. - As of October 31, *ST Suwu's stock price had dropped 88.73% since being investigated by the CSRC, leading to significant losses for shareholders [8]. Operational Challenges - The company reported a revenue of 784 million yuan for the first three quarters of 2025, a decrease of 38.85% year-on-year, with a net profit attributable to shareholders of -87.47 million yuan, a decline of 294.03% [10]. - The medical aesthetics business, previously a revenue driver, has stalled due to the termination of exclusive distribution agreements [11]. - *ST Suwu has significant issues with fund occupation, with non-operating fund occupation by related parties reaching 1.27 billion, 1.393 billion, 1.543 billion, and 1.693 billion yuan at the end of 2020, 2021, 2022, and 2023, respectively [12]. Legal and Financial Status - The company is involved in a tax fraud case, with a court ruling requiring the return of 16 million yuan in illegal gains [12]. - The controlling shareholder's 123 million shares are fully pledged or under judicial restrictions [13].

重要风险提示： 一、公司股票可能被终止上市的原因 根据《股票上市规则》第 9.2.1 条第一款的规定：在上交所仅发行 A 股股票 的上市公司，如果连续 20 个交易日的每日股票收盘价均低于 1 元，公司股票可 能被上交所终止上市交易。公司股票 2025 年 10 月 31 日收盘价为 0.99 元/股， 低于人民币 1 元。如果出现"连续 20 个交易日的每日股票收盘价均低于人民币 1 元"的情形，公司股票可能被上交所终止上市交易。 江苏吴中医药发展股份有限公司(以下简称"公司")股票 2025 年 10 月 31 日收盘价为 0.99 元/股，低于人民币 1 元。根据《上海证券交易所股 票上市规则》（以下简称"《股票上市规则》"）第 9.2.1 条第一款第 一项规定，在上海证券交易所（以下简称"上交所"）仅发行 A 股股票 的上市公司，如果连续 20 个交易日的每日股票收盘价均低于 1 元，公司 股票可能被上交所终止上市交易。根据《股票上市规则》第 9.6.1 条规 定，交易类强制退市公司股票不进入退市整理期交易。 2025 年 7 月 13 日，公司收到中国证券监督管理委员会（以下简称"中 国证监会"）下 ...

Group 1: New Stock Issuances - Multiple new stock issuances are scheduled for October 31, 2025, including Jiangbolong (301308) and Shikong Technology (605178) [1] - A total of 30 companies have announcements related to stock issuance or trading on this date [1] Group 2: Trading Alerts - Jiangbolong (301308) reported severe abnormal fluctuations in trading [1] - Other companies such as ST Wanfang (000638) and Yashichuangneng (603378) also have trading alerts on the same date [1] Group 3: Recent Announcements - Recent announcements include companies like Tianpu Co. (605255) and Kangsheng Co. (002418) with updates on October 31, 2025 [1] - The announcements cover various sectors, indicating a broad market activity [1]

Core Viewpoint - The company faces significant risks of being delisted due to allegations of financial misconduct, including inflated revenue and profits from 2020 to 2023, as identified by the China Securities Regulatory Commission (CSRC) [11][14][15]. Financial Performance - For the first nine months of 2025, the company's aesthetic biomedical business generated revenue of 303.61 million yuan, an increase of 52.78% compared to the previous year [21]. - The pharmaceutical business reported revenue of 468.06 million yuan, a decrease of 55.79% year-on-year, with the pharmaceutical manufacturing segment contributing 345.22 million yuan and the pharmaceutical commerce segment 122.84 million yuan [21]. Regulatory Issues - The company received a notice from the CSRC on July 13, 2025, indicating potential administrative penalties for falsely reporting financial data, which could lead to mandatory delisting [12][14]. - The company has been under investigation since February 26, 2025, for suspected violations of information disclosure laws [13]. Shareholder and Stock Status - The company's controlling shareholder's shares are fully pledged or subject to judicial restrictions, raising concerns about liquidity and control [18]. - The stock has been placed under risk warning due to the ongoing investigation and potential delisting risks [12][16]. Other Operational Risks - The company reported a net loss of 87.47 million yuan for the first three quarters of 2025, a decline of 294.03% compared to the same period last year [18]. - There are unresolved issues regarding non-operational fund occupation by related parties, with significant amounts reported as of the end of 2023 [17].

Group 1 - The core point of the article is that *ST Suwu (600200.SH) reported its Q3 2025 results, highlighting an increase in institutional ownership [1] - As of October 30, 2025, four institutional investors disclosed holding shares in *ST Suwu, totaling 130 million shares, which represents 18.26% of the company's total equity [1] - The institutional investors include Suzhou Wuzhong Investment Holding Co., UBS AG, Hong Kong Central Clearing Limited, and Shaoxing Shangrui Import and Export Co., with a combined ownership increase of 0.63 percentage points compared to the previous quarter [1]

江苏吴中医药发展股份有限公司（以下简称"公司"）主营业务 2025 年 1-9 月主要经营数据情况公告如下： 1、2025 年 1-9 月，公司医美生科业务累计实现主营业务收入 30,360.65 万 元，较上年同期增长 10,488.19 万元，增长 52.78%，医美生科业务主营业务毛利 24,894.97 万元，较上年同期增长 8,565.41 万元，增长 52.45%。 证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-127 江苏吴中医药发展股份有限公司 关于 2025 年 1-9 月主要经营数据的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 2025 年 1-9 月，公司研发累计投入 4,315.86 万元，其中费用化金额 3,409.98 万元，资本化金额 905.88 万元。 特此公告。 江苏吴中医药发展股份有限公司 董事会 2025 年 10 月 31 日 2、2025 年 1-9 月，公司医药业务累计实现主营业务收入 46,806.29 万元（其 中医药工业 34,522.26 万元 ...

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-128 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第十六次风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 江苏吴中医药发展股份有限公司(以下简称"公司")因涉嫌信息披露违 法违规，被中国证券监督管理委员会（以下简称"中国证监会"）立案 调查。2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先 告知书》（处罚字〔2025〕58 号）。认定公司虚增营业收入、营业成本 和利润，2020 年至 2023 年年度报告存在虚假记载，触及重大违法强制 退市情形。公司股票已于 2025 年 7 月 14 日起被叠加实施重大违法类强 制退市风险警示。 如根据正式的处罚决定书结论，公司触及重大违法强制退市情形，公司 股票将被终止上市。根据《上海证券交易所股票上市规则》第 9.5.7 条、 第 9.5.8 条，如公司后续收到行政处罚决定书，显示公司触及重大违法 类强制退市情形，公司将申请停牌，并及时披露有关 ...